Patrick Schoffski

Summary

Affiliation: University Hospitals Leuven
Country: Belgium

Publications

  1. ncbi Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines
    Hans Prenen
    Laboratory for Experimental Oncology LEO, Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Pharmacology 77:11-6. 2006
  2. ncbi Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate
    Hans Prenen
    Departments of General Medical Oncology and Human Genetics, Flanders Interuniversity Institute for Biotechnology VIB, Leuven, Belgium
    Clin Cancer Res 12:2622-7. 2006
  3. ncbi Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma
    Patrick Schoffski
    Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000 Leuven, Belgium
    Future Oncol 3:381-92. 2007
  4. doi Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
    Aljosja Rogiers
    Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium
    Thyroid 20:317-22. 2010
  5. pmc The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I
    Patrick Schoffski
    General Medical Oncology, UZ Leuven, Leuven, Belgium
    BMC Med Imaging 14:19. 2014
  6. ncbi An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
    P Schoffski
    University Hospitals Leuven, KU Leuven, Leuven, Belgium Electronic address
    Eur J Cancer 49:3219-28. 2013
  7. doi Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option
    Patrick Schoffski
    Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Belgium
    Onkologie 35:14-7. 2012
  8. doi Pazopanib in the treatment of soft tissue sarcoma
    Patrick Schoffski
    Department of General Medical Oncology and Laboratory of Experimental Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
    Expert Rev Anticancer Ther 12:711-23. 2012
  9. ncbi Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
    Patrick Schoffski
    University Hospitals Leuven, Catholic University Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium
    Lancet Oncol 12:1045-52. 2011
  10. doi Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies
    P Schoffski
    Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Herestraat 49, 3000 Leuven, Belgium
    Cancer Chemother Pharmacol 68:1397-403. 2011

Detail Information

Publications40

  1. ncbi Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines
    Hans Prenen
    Laboratory for Experimental Oncology LEO, Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Pharmacology 77:11-6. 2006
    ....
  2. ncbi Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate
    Hans Prenen
    Departments of General Medical Oncology and Human Genetics, Flanders Interuniversity Institute for Biotechnology VIB, Leuven, Belgium
    Clin Cancer Res 12:2622-7. 2006
    ..We tested the activity of SU11248, an orally active small-molecule tyrosine kinase inhibitor, to inhibit important imatinib-resistant KIT and PDGFRA mutants...
  3. ncbi Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma
    Patrick Schoffski
    Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000 Leuven, Belgium
    Future Oncol 3:381-92. 2007
    ..Trabectedin is an interesting new anticancer agent that offers much promise for the treatment of advanced soft-tissue sarcoma...
  4. doi Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
    Aljosja Rogiers
    Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium
    Thyroid 20:317-22. 2010
    ..Although sunitinib-induced hypothyroidism seems to be reversible in the majority of patients, some patients develop irreversible thyroid damage resulting in long-lasting thyroid hormone replacement therapy...
  5. pmc The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I
    Patrick Schoffski
    General Medical Oncology, UZ Leuven, Leuven, Belgium
    BMC Med Imaging 14:19. 2014
    ..FDG-PET/CT is part of the standard diagnostic management of a patients with a large variety of common and less common malignant tumors, based on the increased glucose metabolism within tumors...
  6. ncbi An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
    P Schoffski
    University Hospitals Leuven, KU Leuven, Leuven, Belgium Electronic address
    Eur J Cancer 49:3219-28. 2013
    ..Cixutumumab (IMC-A12), a fully human immunoglobulin G1 (IgG1) monoclonal antibody, exerts preclinical activity in several sarcoma models and may be effective for the treatment of these tumours...
  7. doi Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option
    Patrick Schoffski
    Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Belgium
    Onkologie 35:14-7. 2012
    ..Trabectedin is approved in Europe as 24-h intravenous (i.v.) infusion q3w in this setting. We report the use of disposable elastomeric pumps for ambulatory treatment with trabectedin...
  8. doi Pazopanib in the treatment of soft tissue sarcoma
    Patrick Schoffski
    Department of General Medical Oncology and Laboratory of Experimental Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
    Expert Rev Anticancer Ther 12:711-23. 2012
    ..This activity was confirmed in a Phase III trial, where pazopanib significantly extended the median progression-free survival versus placebo in a variety of STS subtypes...
  9. ncbi Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
    Patrick Schoffski
    University Hospitals Leuven, Catholic University Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium
    Lancet Oncol 12:1045-52. 2011
    ..We assessed the activity and safety of eribulin in four strata of patients with different types of soft-tissue sarcoma...
  10. doi Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies
    P Schoffski
    Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Herestraat 49, 3000 Leuven, Belgium
    Cancer Chemother Pharmacol 68:1397-403. 2011
    ..infusion, and to evaluate the safety, efficacy, and pharmacokinetics (PK) of the compound...
  11. doi Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study
    P Schoffski
    Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, B 3000 Leuven, Belgium
    Eur J Cancer 47:1006-12. 2011
    ....
  12. doi A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
    P Schoffski
    Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    Ann Oncol 21:1990-8. 2010
    ..This phase I-II study assessed the safety and efficacy of co-administering everolimus with imatinib in imatinib-resistant GIST...
  13. doi Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research
    Patrick Schoffski
    Department of General Medical Oncology, University Hospitals Leuven, Laboratory of Experimental Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
    Eur J Cancer 46:2206-15. 2010
    ..BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1. We performed a multi-centre, multi-tumour phase II trial to investigate the efficacy, safety and pharmacokinetics of BI 2536 in five solid tumour types...
  14. doi The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors
    Giuseppe Floris
    Laboratory of Experimental Oncology and Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Herestraat 49, bus 815, 3000 Leuven, Belgium
    Mol Cancer Ther 10:1897-908. 2011
    ..The sequence of drug administration in the combination arms warrants further studies...
  15. doi A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal
    Giuseppe Floris
    Department of Pathology, KU Leuven and University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium
    Clin Cancer Res 19:620-30. 2013
    ..Oncogenic signaling in gastrointestinal stromal tumors (GIST) is sustained via PI3K/AKT pathway. We used a panel of six GIST xenograft models to assess efficacy of GDC-0941 as single agent or in combination with imatinib (IMA)...
  16. doi Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies
    Agnieszka Wozniak
    Department of General Medical Oncology and Laboratory of Experimental Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Cancer Invest 28:839-48. 2010
    ..This review examines the potential role of mutational analysis to optimize therapy with imatinib and sunitinib for GIST...
  17. ncbi Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma
    Patrick Schoffski
    Catholic University Leuven, University Hospital Gasthuisberg, Department of General Medical Oncology, Leuven Cancer Institute, Herestraat 49, 3000 Leuven, Belgium
    Expert Opin Pharmacother 9:1609-18. 2008
    ..In this setting, the DNA and transcription interacting agent trabectedin (ecteinascidin-743), isolated originally from the tunicate Ecteinascidia turbinata, has encouraging activity and is now approved in the European Union...
  18. doi High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model
    Giuseppe Floris
    Department of General Medical Oncology, Laboratory of Experimental Oncology, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium
    Clin Cancer Res 15:4066-76. 2009
    ....
  19. ncbi Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial
    Hans Prenen
    Department of General Medical Oncology, Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium
    Acta Gastroenterol Belg 69:367-71. 2006
    ..The only effective treatment for malignant GIST was surgery until 2000. Imatinib mesylate (STI571, Glivec) has shown substantial anticancer activity in patients with metastatic or unresectable GIST...
  20. doi Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma
    Barbara Dewaele
    Department of Human Genetics, University of Leuven, Herestraat 49, B 3000 Leuven, Belgium
    Cancer Res 70:7304-14. 2010
    ....
  21. ncbi Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography
    Hans Prenen
    Laboratory for Experimental Oncology LEO, Department of General Medical Oncology, Catholic University Leuven, B 3000 Leuven, Belgium
    Anticancer Res 26:1247-52. 2006
    ..As resistance to imatinib causes therapy failure, our aim was to develop an in vivo GIST model to evaluate KIT inhibitors and monitor therapy with small animal positron emission tomography (PET)...
  22. doi Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation
    Barbara Dewaele
    Department of Human Genetics, K U Leuven, and VIB Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
    Clin Cancer Res 14:5749-58. 2008
    ..In addition, we sought to investigate the inhibitory effect of the heat shock protein 90 inhibitor, IPI-504, on these mutants...
  23. ncbi Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection
    Gunther Guetens
    Lab of Experimental Oncology, KU Leuven UZ Gasthuisberg, Department of General Medical Oncology, Leuven, Belgium
    J Chromatogr B Analyt Technol Biomed Life Sci 846:341-5. 2007
    ..Calibration curves were linear from 50 to 7500 ng/ml with correlation coefficients (r(2)) better than 0.998. The limit of quantitation (LOD) was 50 ng/ml. The method has been successfully applied to a cellular kinetics study...
  24. ncbi Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management
    Pascal Wolter
    Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, B 3000 Leuven, Belgium
    Acta Oncol 49:13-23. 2010
    ..We also review available data on the potential mechanisms by which these agents may cause adverse events (AEs) and we propose some general strategies to help clinicians to optimise treatment benefit with these agents...
  25. ncbi Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA
    Thomas De Raedt
    Department of Human Genetics, Catholic University of Leuven, Leuven, Belgium
    Gastroenterology 131:1907-12. 2006
    ..At present, the molecular basis of intestinal neurofibromatosis remains elusive. The aim of the present study was to find the gene responsible for intestinal neurofibromatosis and to characterize functionally the mutation...
  26. doi Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours
    Patrick Schoffski
    Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
    Eur J Cancer 47:2256-64. 2011
    ..Aurora B activity was inhibited in tumour tissue, but clinical or metabolic antitumour activity was limited...
  27. doi A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
    Patrick Schoffski
    Department of General Medical Oncology and Laboratory of Experimental Oncology, University Hospitals, Leuven Cancer Institute, Leuven, Belgium
    Eur J Cancer 48:179-86. 2012
    ..This phase I dose-escalation study evaluated the maximum tolerated dose (MTD) of volasertib, safety and efficacy, and pharmacokinetic (PK) parameters...
  28. ncbi Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib
    Benoit Beuselinck
    Department of General Medical Oncology and Laboratory for Experimental Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium Inserm U674 Génomique fonctionnelle des tumeurs solides, Universite Paris 5 Rene Descartes, Paris, France
    BJU Int 114:81-9. 2014
    ..To evaluate the impact of baseline serum C-reactive protein (CRP) level on outcome in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib...
  29. ncbi Clinical presentation, pathological features and natural course of metastatic uveal melanoma, an orphan and commonly fatal disease
    Linda Cerbone
    Department of General Medical Oncology and Laboratory of Experimental Oncology, University Hospitals and Catholic University Leuven, Leuven, Belgium
    Oncology 86:185-9. 2014
    ..Uveal melanoma (UM) is a rare disease characterized by an unpredictable course and a variable outcome. We assessed the natural course of patients with metastatic uveal melanoma (MUM)...
  30. pmc Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma
    Patrick Schoffski
    University Hospital Leuven, Catholic University Leuven, Leuven, Belgium
    Mar Drugs 7:57-70. 2009
    ..Coadministration of L-carnitine did not prevent muscular toxicity or CPK-elevation associated with Plitidepsin...
  31. doi A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance
    Joost Berkers
    Laboratory of Translational Cell and Tissue Research, Catholic University Leuven, Leuven, Belgium
    J Urol 189:1930-8. 2013
    ..We identified microRNA driven mechanisms in clear cell renal cell carcinoma associated with the tumor response to the multitargeted receptor tyrosine kinase inhibitor sunitinib...
  32. pmc Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium
    Herlinde Dumez
    University Hospitals Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000 Leuven, Belgium
    Mar Drugs 7:451-63. 2009
    ..No severe neutropenia occurred. Treatment was feasible and generally well tolerated in this patient population; however the lack of antitumor activity precludes further studies of plitidepsin in this setting...
  33. ncbi Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium
    Invest New Drugs 26:483-8. 2008
    ..Vorinostat in a daily oral schedule for 14 days/3 weeks was tolerable at 200 mg bid only, and no responses were observed in this study. Most patients, however, had limited drug exposure which did not allow a reliable efficacy analysis...
  34. doi Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology
    Patrick Schoffski
    Department of General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium
    Oncologist 14:559-70. 2009
    ..e., ZK-thiazolidinone, NMS-1, CYC-800, DAP-81, and LC-445). If proof of principle is confirmed in large studies, PLK inhibitors will offer a new targeted antitumor therapy for cancer patients...
  35. doi VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis
    Benoit Beuselinck
    Department of General Medical Oncology and Laboratory for Experimental Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
    Acta Oncol 53:103-12. 2014
    ..Here, we aim to study the impact of these SNPs in mRCC patients treated with sunitinib...
  36. ncbi Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease
    Patrick Schoffski
    Department of General Medical Oncology and Laboratory of Experimental Oncology, Leuven Cancer Institute, KU Leuven, Belgium
    Oncol Res Treat 37:355-62. 2014
    ....
  37. ncbi Cabozantinib in progressive medullary thyroid cancer
    Rossella Elisei
    Rossella Elisei, University of Pisa, Pisa Lisa Licitra, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy Martin J Schlumberger, Institut Gustave Roussy, University Paris Sud, Villejuif, France Stefan P Müller, Universitatsklinikum Essen, Essen Michael C Kreissl, Universitatsklinikum Wurzburg, Wurzburg, Germany Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium Marcia S Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA Manisha H Shah, Ohio State University Medical Center, Columbus, OH Barbara Jarzab, Centrum Onkologii Instytut im Marii Skłodowskiej Curie Oddział w Gliwicach, Gliwice, Poland Viktor Medvedev, Medical Radiological Research Centre of the Russian Academy of Medical Sciences, Obninsk, Russia Bruno Niederle, Medizinische Universität Wien, Wien, Austria Ezra E W Cohen, University of Chicago, Chicago, IL Lori J Wirth, Massachusetts General Hospital, Boston, MA Haythem Ali, Henry Ford Health System
    J Clin Oncol 31:3639-46. 2013
    ....
  38. doi Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors
    Pauline Lagarde
    INSERM U916 Genetics and Biology of Sarcomas, Paris Cedex, France
    Clin Cancer Res 18:826-38. 2012
    ..We recently published a 67 gene expression prognostic signature related to genome complexity (CINSARC for Complexity INdex in SARComas) and asked whether it could predict outcome in GISTs...
  39. doi Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs
    Mattia Quattrocelli
    Translational Cardiomyology, Stem Cell Institute, Katholieke Universiteit Leuven, Herestraat 49, Leuven, Belgium
    J Pathol 223:593-603. 2011
    ..Our data strongly suggest that iPSCs are a heterogeneous population and, when generated from myogenic adult stem cells, they exhibit a stronger commitment, paving the way for creating custom-made cell protocols for muscular dystrophies...
  40. doi A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma
    Patrick Schoffski
    Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
    BJU Int 108:679-86. 2011
    ..To evaluate the efficacy and safety of single-agent AMG 102, an investigational, fully human monoclonal antibody to hepatocyte growth factor/scatter factor (HGF/SF), in renal cell carcinoma (RCC)...